Ultimately depletion of JMY sensitises cells to DDR inhibitors and impacts on cell survival and this is reflected in human cancers where a lack of, or decreased, JMY mRNA expression results in better overall survival and increased tumour mutation count (Fig. 6h). This evidence concerns the gene JMY and cancer.